UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of December 2023

Commission File Number: 001-37452

 

 

CELYAD ONCOLOGY SA

(Translation of registrant’s name into English)

 

 

9 rue André Dumont

1435 Mont-Saint-Guibert, Belgium

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40- F.

Form 20-F  ☒                Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


Celyad Oncology SA

On December 20, 2023, Celyad Oncology SA (the “Company”) issued a press release announcing that in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), it received a notification of transparency dated December 19, 2023 indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 55%. CFIP CLYD (UK) Limited holds 29,358,654 voting rights, representing 58.37 % of the Company’s voting rights.

A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Current Report on Form 6-K, including Exhibit 99.1 is hereby incorporated by reference into the Company’s Registration Statements on Forms F-3 (File No. 333-248464) and S-8 (File No. 333- 220737).

EXHIBITS

 

Exhibit    Description
99.1    Press release issued by the registrant on December 20, 2023


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    CELYAD ONCOLOGY SA
Date: December 21, 2023     By:   /s/ Michel Lussier
            Mel Management represented by Michel Lussier
            Chief Executive Officer ad interim

Exhibit 99.1

 

LOGO

   Press Release - Regulated Information

Publication of a transparency notification received from Fortress Investment Group LLC

(Article 14 §1 of the Law of 2 May 2007)

Mont-Saint-Guibert, Belgium, December 20, 2023, 10.01 pm CET—regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency dated December 19, 2023, indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 55%, holding 29,358,654 voting rights, i.e. 58.37 % of Celyad Oncology’s voting rights.

Content of the Notification:

 

   

Reason of the Notification:

Passive crossing of a threshold

 

   

Notification by:

A parent undertaking or a controlling person

 

   

Persons subject to the notification requirement:

Fortress Investment Group LLC—1345 Avenue of the Americas, New York, NY 10105 United States

CFIP CLYD (UK) Limited—7 Clarges Street, 4th Floor, London W1J 8AE, United Kingdom

 

   

Date on which the threshold is crossed:

December 8, 2023

 

   

Threshold that is crossed (in %):

55

 

   

Denominator:

50,296,947

 

   

Notified details:

 

A) Voting Rights

   Previous      After the Transaction  
     notification.      # of voting rights      % of voting rights  

Holders of voting rights

   # of voting rights     

Linked to the
securities

    

Not linked to
the securities

    

Linked to the
securities

   

Not linked to
the securities

 

Fortress Investment Group LLC

     0        0        0        0.00     0.00

CFIP CLYD (UK) Limited

     22,858,654        29,358,654        0        58.37     0.00

Subtotal

     22,858,654        29,358,654           58.37  
     

 

 

    

 

 

    

 

 

   

 

 

 

TOTAL

        29,358,654        0        58.37     0.00
     

 

 

    

 

 

    

 

 

   

 

 

 

 

Page 1 of 3


LOGO

   Press Release - Regulated Information

 

B) Equivalent financial instruments

  

After the transaction

 

Holders of equivalent financial instruments

  

Type of financial
instrument

    

Expiration
date

  

Exercise
period or
date

  

# of voting
rights that may
be acquired if
the instrument
is exercised

    

% of
voting
rights

   

Settlement

 

TOTAL

           0        0.00  
           

 

 

    

 

 

   

 

TOTAL (A & B)

  

# of voting
rights

    

% of voting rights

 

CALCULATE

     29,358,654        58.37

 

   

Full chain of controlled undertakings through which the holdings is effectively held:

 

   

CFIP CLYD (UK) Limited (“CFIP UK”), a United Kingdom limited liability company and a wholly- owned subsidiary of CFIP, directly holds 22,858,654 Ordinary Shares.

 

   

CFIP CLYD LLC, a Delaware limited liability company (“CFIP”), is the parent of CFIP UK.

 

   

FIP II UB Investments LP, a Delaware limited partnership (“FIP II”), holds 50% of the membership interests in CFIP.

 

   

FIP Fund II GP LLC, a Delaware limited liability company (“FIP II GP”), is the general partner of FIP II.

 

   

Hybrid GP Holdings LLC, a Delaware limited liability company (“Hybrid GP”), is the parent of FIP II GP and indirectly controls the general partners of certain investment funds that hold membership interests in CFIP.

 

   

FIG LLC, a Delaware limited liability company (“FIG LLC”), indirectly controls the investment advisers to certain investment funds that hold membership interests in CFIP.

 

   

Fortress Operating Entity I LP, a Delaware limited partnership (“FOE I”), is (i) the sole owner of FIG LLC and (ii) the managing member of, and holds the majority of equity interest in, Hybrid GP.

 

   

FIG Corp., a Delaware corporation (“FIG Corp.”), is the general partner of FOE I.

 

   

Fortress Investment Group LLC, a Delaware limited liability company (“Fortress”), is the sole owner of FIG Corp and has no controlling shareholder.

 

   

Additional information:

This transparency notification covers the passive crossing of the 55% threshold due to receiving double voting rights on 6,500,000 shares of CFIP CLYD (UK) Limited as of December 8, 2023. As a result, CFIP CLYD (UK) Limited currently holds 29,358,654 voting rights.

Miscellaneous

 

   

The Press Release may be consulted on the website of Celyad Oncology:

https://celyad.com/newsroom/

 

   

The notification can be consulted on the website of Celyad Oncology:

https://celyad.com/investors/regulated-information/

 

   

Contact person(s): Any transparency notification must be sent to our Company by email to the attention of Michel Lussier, Chief Executive Officer (CEO) ad interim: investors@celyad.com

 

Page 2 of 3


LOGO

   Press Release - Regulated Information

 

About Celyad Oncology

Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.

Forward-looking statements

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding beliefs about and expectations for the Company’s updated strategic business model, including associated potential benefits, transactions and partnerships, statements regarding the potential value of the Company’s IP, and statements regarding the transparency notification. The words “will,” “believe,” “potential,” “continue,” “target,” “project,” “should” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on management’s current expectations and beliefs and are subject to a number of known and unknown risks, uncertainties and important factors which might cause actual events, results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks related to the material uncertainty about the Company’s ability to continue as a going concern; the Company’s ability to realize the expected benefits of its updated strategic business model; the Company’s ability to develop its IP assets and enter into partnerships with outside parties; the Company’s ability to enforce its patents and other IP rights; the possibility that the Company may infringe on the patents or IP rights of others and be required to defend against patent or other IP rights suits; the possibility that the Company may not successfully defend itself against claims of patent infringement or other IP rights suits, which could result in substantial claims for damages against the Company; the possibility that the Company may become involved in lawsuits to protect or enforce its patents, which could be expensive, time-consuming, and unsuccessful; the Company’s ability to protect its IP rights throughout the world; the potential for patents held by the Company to be found invalid or unenforceable; and other risks identified in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Celyad Oncology Contacts:

 

Investor and Media Contact:

David Georges

VP Finance and Administration

investors@celyad.com

 

LOGO

 

Source: Celyad Oncology SA

 

Page 3 of 3